اسم المؤلف:
اسيل نجاح صبر
اسم المشرف:
احسان ريسان ابراهيم الركابي
المستخلص:
هدفت هذه الدراسة الى تحديد تاثيرات مادة بنزوات الصوديوم في مستويات بعض الهرمونات ومؤشرات الاجهاد التاكسدي والمعايير الكيموحيوية في ذكور الجرذان البالغة وغير البالغة ولمدد مختلفة. ولبيان هذه التاثيرات صممت تجربتين رئيستين لهذه الدراسة، استعمل في التجربة ا | This study was aimed to determining the effects of sodium benzoate in the levels of some hormones and oxidative stress indicators as well as biochemical parameters in mature and immature albino male rats in different durations.To detect these effects two main experiments were designed in the current study, (60) immature male rats were used in the first main experiment that included three secondary experiments each one of these was included four groups of immature albino male rats, (5) male for each group.In the first secondary experiment G1, G2, and G3 groups were orally given sodium benzoate daily in concentrations of 50, 100, 200 mg/ kg of body weight for one week, whereas in the second and the third secondary experiments G1, G2, and G3 groups were orally given sodium benzoate in the same concentrations daily for two and three weeks respectively. The control groups of the three secondary experiments were given distilled water throughout experiments. (60) of mature male rats were used in the second main experiment that have included the same design as the previous one.After the end of treatments in each experiment, the following parameters were studied : hormonal parameters that included corticosterone, luteinizing hormone LH, testosterone T, thyroid stimulating hormoneTSH and thyroxin T4, oxidative stress indicators (glutathione and malodialdehyde) and biochemical parameters that included (liver enzymes ALT and AST, total bilirubin, albumin, globuoline, total serum protein, sodium and potassium).The results of the first main experiment are pointed out : 1 - A significant increase(P<0.05) in the level of corticosterone hormone in both G2 and G3 groups during one weak of treatment and in G1, G2, and G3 groups during two and three weeks of each treatment. 2 - A significant decrease (P<0.05) in the levels of luteinizing hormone and testosterone in G3 group also the thyroid stimulating hormone and thyroxin in both G2 and G3 groups during one week of treatment, the levels of all these hormones were also revealed a significant decrease (P<0.05) in the G1, G2, and G3 groups during two and three weeks of treatment. 3 - A significant decrease (P<0.05) in the glutathione level was accompanied by a significant increase in the malondialdehyde level in both G2 and G3 groups during one week of treatment and also in the G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups. 4 - A significant increase (P<0.05) in the ALT and AST enzymes levels in G1, G2 and G3 groups during each duration of experiment in comparison with control groups. 5 - A significant increase(P<0.05) in the total bilirubin level in both G2 and G3 groups during one week of treatment. Also in G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups. 6 - A significant decrease(P<0.05) in the albumin and total serum protein levels in both G2 and G3 groups during one week of treatment, the decreased albumin and globuline levels were also accompanied by a significant decrease (P<0.05) in the level of total serum protein in G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups.7 - A significant increase(P<0.05) in the sodium level in G1, G2, and G3 groups during each duration of experiment in comparison with control groups. 8 - A significant increase (P<0.05) in the potassium level in both G2 and G3 groups during one week of treatment and in G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups. 9 - Comparison between treatments durations for all parameters was showed a significant difference (P<0.05) in levels of most parameters during two and three weeks of treatment in both G1 and G2 and with increasment of treatment duration in G3. The results of the second main experiment were presented that : 1 - A significant increase (P<0.05) in the corticosterone level in G3 during one week of treatment also in both G2 and G3groups during two weeks of treatment as well as in G1, G2, and G3 groups during three weeks of treatment in comparison with control groups. 2 - A significant decrease (P<0.05) in the levels of luteinizing hormone, testosterone, thyroid stimulating hormone and thyroxin in both G2 and G3 groups during two weeks of treatment and in G1, G2, and G3 groups during three weeks of treatment in comparison with control groups. 3 - A significant decrease(P<0.05) in the glutathione level was accompanied by a significant increase in the malondialdehyde level in both G1and G2 during two weeks of treatment, as well as in G1, G2, and G3 groups during three weeks of treatment in comparison with control groups. 4 - A significant increase(P<0.05) in the ALT and AST enzymes levels in the G1, G2 and G3 groups during each duration of experiment in comparison with control groups. 5 - A significant increase(P<0.05) in the total bilirubin level in G3group during one week treatment, also in G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups. 6 - A significant decrease(P<0.05) in the albumin and total serum protein levels in G3 group during one weak treatment, also in G1, G2, and G3 groups during two weeks treatment. The significant decrease(P<0.05) in the albumin and globuline levels in G1, G2, and G3 groups during three weeks treatment was accompanied by a significant decrease in the total serum protein level in compare with control groups.7 - A significant increase (P<0.05) in the sodium and potassium levels in G1, G2, and G3 groups during two and three weeks of treatment in comparison with control groups.8 - Comparison between treatments durations for all parameters was showed a significant difference (P<0.05) in levels of most parameters during three weeks of treatment in G1 and during two and three weeks of treatment in G2 and G3.
